Maurie Markman

One of the more perplexing issues surrounding scientific questions is the extended time required to provide an answer. Even once a well-considered and vetted conclusion is obtained, an additional interval of time may be required to modify or reverse the answer because of new, relevant data.

Much has been written regarding the essential role of clinical trials in the major advances in cancer therapy and observed improvement in disease-related morbidity and mortality.

It is difficult to dispute that these are troubling times for government officials and public health agencies.

Costs associated with anticancer therapeutics continue to rise, although it also is recognized that the overall effectiveness of therapy has improved.

Maurie Markman, MD, discusses how privacy and consent in clinical cancer trials have improved over the years.

The repercussions of delays in diagnosing cancer, either through screening or the presence of early symptoms, and of required modifications in standard-of-care management paradigms in the COVID-19 era are only now beginning to be fully appreciated.

The management of carcinoma of the cervix represents a remarkable dichotomy.

When is it appropriate to accept a specific strategy, either formally or informally, as a standard-of-care option in managing the treatment of patients with cancer in a particular clinical setting?

Maurie Markman, MD, president, Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses when patients with ovarian cancer should undergo a bilateral salpingo-oophorectomy (BSO).